Protocol Ledger

NCT06463587 · Phase III · RECRUITING

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Interventional Phase III clinical trial protocol NCT06463587 sponsored by EMD Serono / Merck KGaA in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-25 Enrollment: 264 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06463587
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)264 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06463587
Protocol FieldVerified Registry Value
NCT IdentifierNCT06463587
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment264 participants (ESTIMATED)
Registered Start Date2024-06-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06463587
Hospital Research SiteLocationSite Profile
Miami Valley Hospital SouthCenterville, OHOpen Hospital Dossier ->
University of CincinnatiCincinnati, OHOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI